Read More Pharma Industry News Neumora Therapeutics’ KOASTAL-1 study of navacaprant for MDD falls short on primary endpoint Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company specialising in neuroscience, has announced results from the KOASTAL-1… byPallavi MadhirajuJanuary 2, 2025